Shareholders are very likely to turn down the Michael Saylor pitch, Polymarket bettors are predicting. …
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients …